FDA and EMA Expectations for OOS Reporting in Stability Studies
Out-of-Specification (OOS) results in stability testing demand thorough investigation, prompt documentation, and transparent communication with regulators. Both the FDA and EMA have issued detailed expectations for how pharmaceutical companies should manage and report such occurrences. Understanding the nuances between these regulatory bodies is essential for global compliance. This article outlines key differences and best practices…
Read More “FDA and EMA Expectations for OOS Reporting in Stability Studies” »